van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T
Ludwig Institute for Cancer Research, Brussels, Belgium.
Science. 1991 Dec 13;254(5038):1643-7. doi: 10.1126/science.1840703.
Many human melanoma tumors express antigens that are recognized in vitro by cytolytic T lymphocytes (CTLs) derived from the tumor-bearing patient. A gene was identified that directed the expression of antigen MZ2-E on a human melanoma cell line. This gene shows no similarity to known sequences and belongs to a family of at least three genes. It is expressed by the original melanoma cells, other melanoma cell lines, and by some tumor cells of other histological types. No expression was observed in a panel of normal tissues. Antigen MZ2-E appears to be presented by HLA-A1; anti-MZ2-E CTLs of the original patient recognized two melanoma cell lines of other HLA-A1 patients that expressed the gene. Thus, precisely targeted immunotherapy directed against antigen MZ2-E could be provided to individuals identified by HLA typing and analysis of the RNA of a small tumor sample.
许多人类黑色素瘤肿瘤表达的抗原,在体外能被来自荷瘤患者的细胞毒性T淋巴细胞(CTL)识别。已鉴定出一个基因,该基因指导抗原MZ2-E在一种人类黑色素瘤细胞系上表达。此基因与已知序列无相似性,属于一个至少由三个基因组成的家族。它在原始黑色素瘤细胞、其他黑色素瘤细胞系以及其他组织学类型的一些肿瘤细胞中表达。在一组正常组织中未观察到表达。抗原MZ2-E似乎由HLA-A1呈递;原始患者的抗MZ2-E CTL识别了其他两名HLA-A1患者的两个表达该基因的黑色素瘤细胞系。因此,针对抗原MZ2-E的精确靶向免疫疗法可提供给通过HLA分型和小肿瘤样本RNA分析鉴定出的个体。